NCT03804372 2025-02-27
CLL1818
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
Clinical Trials
9 trialsNCT01518959 2020-07-16
D-HEM
Semmelweis University
Phase 3 Terminated
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01446900 2018-01-31
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
European Institute of Oncology
Phase 2 Terminated
NCT00714259 2017-07-24
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
University of Alabama at Birmingham
Phase 2/3 Terminated
NCT00751296 2016-06-16
Rev-CLL
University Health Network, Toronto
Phase 2 Terminated
NCT01119794 2015-08-26
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
Phase 2 Terminated
NCT01463852 2015-05-12
A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)
Dartmouth-Hitchcock Medical Center
Phase EARLY_PHASE1 Terminated
NCT01127542 2011-12-05
RESPeCT
The Christie NHS Foundation Trust
Phase 2 Terminated